Bacil Pharma Subsidiary Signs ₹35 Crore R&D Agreement with Efdee Pharma
Bacil Pharma Ltd · Others (Uncategorized) · 05 Nov 2026, 12:04 am
Bacil Pharma Subsidiary Signs ₹35 Crore R&D Agreement with Efdee Pharma Bacil Pharma Limited announced that its wholly owned subsidiary, Bacil Research and Development Private Limited, entered into an R&D agreement with Efdee Pharma Private Limited on 4th Nov'26. The project focuses on research and development activities for pharmaceutical products, covering pellets, granules, powders, tablets, and capsules. The total estimated cost of the project is ₹35.00 crore.
Original exchange filing (PDF)
More announcements from Bacil Pharma Ltd
- Un-Audited Financial Results for the Quarter and Half Yearly Ended 30th September, 2026 · 14 Oct 2026
- Outcome of Board Meeting held on 14th October, 2026 · 14 Oct 2026
- Intimation for resignation of Company Secretary · 09 Oct 2026
- Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/10/2026 ,inter alia, to consider and approve 1. Unaudited Financial Results .... · 14 Oct 2026
- Scrutinizers Report for the Annual General Meeting of the Company for FY 2025-2026 · 24 Sept 2026
- Outcome/Proceeding of Annual General Meeting of the Company · 23 Sept 2026
- Annual Report for the Financial Year 2025-2026 · 31 Aug 2026
- Notice of Annual General Meeting to be held on 23rd September, 2026 · 30 Aug 2026
